In line with the results from the TCGA dataset, the patients with higher SERPINE1 expression also exhibited shorter overall survival in the CGGA dataset (P<0.001 for all LGGs, P=0.042 for WHO grade II gliomas, and P<0.001 for WHO grade III gliomas) (Figures 5D–F). This evidence concerns the gene SERPINE1 and glioma.